Abafungin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Abafungin
Accession Number
DB06395
Type
Small Molecule
Groups
Investigational
Description
Not Available
Structure
Thumb
Synonyms
  • abafungina
  • abafungine
  • abafunginum
External IDs
BAY W 6341 / BAY-W-6341
International/Other Brands
Abasol
Categories
UNII
11DI31LWXF
CAS number
129639-79-8
Weight
Average: 378.49
Monoisotopic: 378.151432518
Chemical Formula
C21H22N4OS
InChI Key
TYBHXIFFPVFXQW-UHFFFAOYSA-N
InChI
InChI=1S/C21H22N4OS/c1-14-8-9-18(15(2)12-14)26-19-7-4-3-6-16(19)17-13-27-21(24-17)25-20-22-10-5-11-23-20/h3-4,6-9,12-13H,5,10-11H2,1-2H3,(H2,22,23,24,25)
IUPAC Name
N-{4-[2-(2,4-dimethylphenoxy)phenyl]-1,3-thiazol-2-yl}-1,3-diazinan-2-imine
SMILES
CC1=CC=C(OC2=CC=CC=C2C2=CSC(N=C3NCCCN3)=N2)C(C)=C1

Pharmacology

Indication

Investigated for use/treatment in fungal infections, bacterial infection, skin infections/disorders, and onychomycosis.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action

Abafungin has been shown to have fungicidal and fungistatic effects on a wide variety of pathogens, including dermatophytes, yeasts (Candida) and moulds. The drug acts on the infecting organisms in two ways: by interfering with the formation of a vital sterol in the fungal cell membrane, thereby preventing cell growth, and also by direct interaction with another membrane component resulting in membrane disruption, leakage of cellular contents and death of the cell and independent of whether it is in a non-metabolising (`resting') phase of development or actively growing. These features of abafungin, combined with the attainment of microbicidal concentrations in the skin from a 1% preparation, its long residence at the site of dermal application and the lack of significant systemic absorption, mean that Abasol(tm) is particularly attractive for the topical treatment of dermatomycoses, which is the first indication under review for marketing approval.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AtorvastatinThe risk or severity of adverse effects can be increased when Abafungin is combined with Atorvastatin.Approved
CerivastatinThe risk or severity of adverse effects can be increased when Abafungin is combined with Cerivastatin.Withdrawn
FluvastatinThe risk or severity of adverse effects can be increased when Abafungin is combined with Fluvastatin.Approved
LovastatinThe risk or severity of adverse effects can be increased when Abafungin is combined with Lovastatin.Approved, Investigational
MevastatinThe risk or severity of adverse effects can be increased when Abafungin is combined with Mevastatin.Experimental
PitavastatinThe risk or severity of adverse effects can be increased when Abafungin is combined with Pitavastatin.Approved
PravastatinThe risk or severity of adverse effects can be increased when Abafungin is combined with Pravastatin.Approved
RosuvastatinThe risk or severity of adverse effects can be increased when Abafungin is combined with Rosuvastatin.Approved
SimvastatinThe risk or severity of adverse effects can be increased when Abafungin is combined with Simvastatin.Approved
UbidecarenoneThe risk or severity of adverse effects can be increased when Abafungin is combined with Ubidecarenone.Approved, Investigational, Nutraceutical
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Abafungin.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
159326
PubChem Substance
347827768
ChemSpider
140124
ChEBI
76005
Wikipedia
Abafungin

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00354 mg/mLALOGPS
logP4.55ALOGPS
logP4.79ChemAxon
logS-5ALOGPS
pKa (Strongest Basic)6.54ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area58.54 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity110.35 m3·mol-1ChemAxon
Polarizability41.5 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylethers. These are aromatic compounds containing two benzene rings linked to each other through an ether group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylethers
Direct Parent
Diphenylethers
Alternative Parents
Diarylethers / m-Xylenes / Phenoxy compounds / Phenol ethers / 2,4-disubstituted thiazoles / Hydropyrimidines / 2-amino-1,3-thiazoles / Heteroaromatic compounds / Guanidines / Propargyl-type 1,3-dipolar organic compounds
show 4 more
Substituents
Diphenylether / Diaryl ether / Phenoxy compound / M-xylene / Xylene / Phenol ether / 2,4-disubstituted 1,3-thiazole / Hydropyrimidine / 1,3-thiazol-2-amine / 1,4,5,6-tetrahydropyrimidine
show 17 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
aromatic ether, guanidines, 1,3-thiazole (CHEBI:76005)

Drug created on March 19, 2008 10:28 / Updated on December 01, 2017 15:39